<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Era of Hope Scholar Award** | Must be an independent, non-mentored investigator within 6 years of his/her last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline. | • Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.  
• Principal Investigators (PIs) should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.  
• PIs should exhibit strong potential for leadership in the breast cancer community.  
• PIs must include breast cancer advocates on their research team. | • The maximum period of performance is 5 years.  
• The maximum allowable funding for the entire period of performance is $2.5 million (M) in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Letter of Intent):  
August 1, 2014  
5:00 p.m. Eastern time (ET)  
Confidential Letters of Recommendation Submission Deadline:  
August 15, 2014  
5:00 ET  
Application:  
August 15, 2014  
11:59 p.m. ET |
| **Innovator Award** | Must be an Associate Professor or above (or equivalent).                                                                                                                                                   | • Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.  
• Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.  
• PIs must include breast cancer advocates on their research team.  
• Nomination is required; self-nominations are accepted; application submission is by invitation only. | • The maximum period of performance is 5 years.  
• The maximum allowable funding for the entire period of performance is $5M in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Nomination):  
May 14, 2014  
5:00 p.m. ET  
Confidential Letters of Recommendation Submission Deadline:  
August 15, 2014  
5:00 ET  
Invited Application:  
August 15, 2014  
11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakthrough Award Levels 1 and 2</td>
<td>Investigators at all academic levels (or equivalent) are eligible.</td>
<td>Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.</td>
<td>Applications may be submitted under one of the following funding levels:</td>
<td>Pre-Application (Letter of Intent): May 14, 2014 5:00 p.m. ET</td>
</tr>
<tr>
<td>Go to:</td>
<td>Postdoctoral fellows are eligible and encouraged to apply; additional applications components are required.</td>
<td>Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.</td>
<td><strong>Funding Level 1:</strong></td>
<td>Application: May 28, 2014 11:59 p.m. ET</td>
</tr>
<tr>
<td>General Application Instructions</td>
<td>Each PI may submit only one application as a single PI or Initiating PI.</td>
<td>Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.</td>
<td>• The maximum allowable funding for the entire period of performance is <strong>$350,000</strong> in direct costs.</td>
<td></td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number: W81XWH-14-BCRP-BREAKTHROUGH12</td>
<td></td>
<td>It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.</td>
<td>• The maximum period of performance is 3 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Submission of a Letter of Intent is required prior to full application submission.</td>
<td><strong>Funding Level 2:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consumer advocate involvement is encouraged, but not required.</td>
<td>• The maximum allowable funding for the entire period of performance is <strong>$700,000</strong> in direct costs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical trials are not allowed.</td>
<td>• The maximum period of performance is 3 years.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Both Funding Levels:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td></td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadline</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
</tbody>
</table>
| Breakthrough Award Levels 3 and 4 | • Independent investigators at all academic levels (or equivalent) are eligible.  
• Each PI may submit only one application as a single PI or Initiating PI. | • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.  
• Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.  
• Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.  
• It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  
• Submission of a preproposal is required; application submission is by invitation only.  
• Clinical trials are allowed.  
• Applicants are required to include breast cancer advocates on their research team. | Applications may be submitted under one of the following funding levels:  
**Funding Level 3:**  
• The maximum allowable funding for the entire period of performance is $2.5M in direct costs.  
• The maximum period of performance is 5 years.  
**Funding Level 4:**  
• The maximum allowable funding for the entire period of performance is $10M in direct costs.  
• The maximum period of performance is 5 years.  
**Both Funding Levels:**  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-Application (Preproposal):  
May 14, 2014  
5:00 p.m. ET  
Invited Application:  
August 15, 2014  
11:59 p.m. ET |

*Grants.gov Funding Opportunity Number: W81XWH-14-BCRP-BREAKTHROUGH34*